Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

CXCL10 (Chemokine (C-X-C motif) ligand 10)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

myPath Melanoma

myPath Melanoma

›

CXCL10 overexpression	Glioblastoma	CXCL10 overexpression	Glioblastoma	aflibercept intravitreal Sensitive: C3 – Early Trials aflibercept intravitreal Sensitive : C3	aflibercept intravitreal Sensitive: C3 – Early Trials aflibercept intravitreal Sensitive : C3
CXCL10 overexpression	Renal Cell Carcinoma	CXCL10 overexpression	Renal Cell Carcinoma	pembrolizumab + axitinib Sensitive: C3 – Early Trials pembrolizumab + axitinib Sensitive : C3	pembrolizumab + axitinib Sensitive: C3 – Early Trials pembrolizumab + axitinib Sensitive : C3
CXCL10 elevation	Uveal Melanoma	CXCL10 elevation	Uveal Melanoma	tebentafusp-tebn Sensitive: C3 – Early Trials tebentafusp-tebn Sensitive : C3	tebentafusp-tebn Sensitive: C3 – Early Trials tebentafusp-tebn Sensitive : C3
CXCL10 elevation	Cutaneous Melanoma	CXCL10 elevation	Cutaneous Melanoma	tebentafusp-tebn Sensitive: C3 – Early Trials tebentafusp-tebn Sensitive : C3	tebentafusp-tebn Sensitive: C3 – Early Trials tebentafusp-tebn Sensitive : C3
CXCL10 elevation	Endometrial Cancer	CXCL10 elevation	Endometrial Cancer	pembrolizumab + lenvatinib Sensitive: C3 – Early Trials pembrolizumab + lenvatinib Sensitive : C3	pembrolizumab + lenvatinib Sensitive: C3 – Early Trials pembrolizumab + lenvatinib Sensitive : C3
CXCL10 elevation	Renal Cell Carcinoma	CXCL10 elevation	Renal Cell Carcinoma	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3
CXCL10 elevation	Renal Cell Carcinoma	CXCL10 elevation	Renal Cell Carcinoma	sunitinib Resistant: C3 – Early Trials sunitinib Resistant : C3	sunitinib Resistant: C3 – Early Trials sunitinib Resistant : C3
CXCL10 elevation	Renal Cell Carcinoma	CXCL10 elevation	Renal Cell Carcinoma	sunitinib + pazopanib Resistant: C3 – Early Trials sunitinib + pazopanib Resistant : C3	sunitinib + pazopanib Resistant: C3 – Early Trials sunitinib + pazopanib Resistant : C3
PD-L1 elevation + CXCL10 elevation + TNFA elevation	Melanoma	PD-L1 elevation + CXCL10 elevation + TNFA elevation	Melanoma	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
CXCL10 expression	Bladder Cancer	CXCL10 expression	Bladder Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
CXCL10 overexpression + LAMP3 overexpression	Bladder Cancer	CXCL10 overexpression + LAMP3 overexpression	Bladder Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
CXCL10 elevation	Acute Myelogenous Leukemia	CXCL10 elevation	Acute Myelogenous Leukemia	venetoclax Resistant: D – Preclinical venetoclax Resistant : D	venetoclax Resistant: D – Preclinical venetoclax Resistant : D